…And the BEAT Goes On

Written by GSCR Staff   
Wednesday, 22 July 2015 06:38

So what does the title from the 1979 the Whispers hit, or for our younger viewers, the cover for Will Smith’s, Miami, have to do with the stock market?

We think we have covered our bases on this in the last two editions of the Goldman Guide. Financial results, i.e. earnings, are crucial. Additionally, the huge reversal of the P/E ratio for NASDAQ 100 relative to the Russell 2000 means that some nice tailwinds ahead for small caps. Today we look at the small cap bellwether, healthcare technology. And the beat goes on.

 

BioTelemetry, Inc. (NASDAQ – BEAT - $11.29) is an up and comer on an impressive run as illustrated by the chart below. We featured the stock back in October of last year at $7.30. The 55% price increase is well above our original $9 target.

 

BEAT 1-Year Chart, 200-Day EMA

(Source: www.otcmarkets.com)

 

MM.07.22.15.BEAT-200ema

 

 

Here is a refresher.   The Company is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  The Company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services.

 

On May 6th the Company reported financial results for Q1 2015 and beat expectations for EPS ($0.06 actual vs. $0.02 estimate) and revenue of $43.4 million was up 17% from Q1 2014. The Company has now beaten EPS estimates four consecutive quarters. Additionally, forecasts for revenue in 2015 are for $185M representing an 11% increase over 2014. Finally, on the technical side, the short float remains relatively low at 3.6%.

 

We think BEAT is a hold for now as some of the deal flow has slowed from our prior coverage but overall metrics remain strong. It may be time to lock in profits with covered calls or protective puts. Our 2015 target is $13. And the BEAT goes on…

 

Have a great day!

 

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations. 

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small CapResearch blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLECONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLECONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com

 

Add comment
  • No comments found